len calabrese managing comorbidities in rheumatologic ... · tom huizinga predicting clinical...
Post on 15-Dec-2018
214 Views
Preview:
TRANSCRIPT
This meeting is sponsored by UCB.CME accreditation applied for.Date of Preparation: October 2012Code: IMNL-SCT-016659-102012 © UCB S.A. 2012. All rights reserved.
You will have the opportunity to attend up to four `mini-symposia’ sessions. A selection of the mini-symposia available is provided below. A full list of available sessions and information on how to pre-register will be provided.
Len Calabrese Managing Comorbidities in Rheumatologic Diseases
Tom Huizinga Predicting Clinical Response – Biomarkers and Genetics
Georgy Nagy Clinical Cases – Management of the Difficult RA patient
Claire Bombardier Quality Indicators in RA
Roy Fleischmann Oral Therapies – Clinical Data
Walter GrassiFred Joshua
To Be or Not to Be in Remission: Can Ultrasound Guide Us?
Annelies BoonenLaure Gossec
Patient Reported Outcomes: Can Patients Tell Us More?
Maxime DougadosFilip Van den Bosch
Update in Spondyloarthropathies
Robert LandewéXenofon Baraliakos
AxSpA: Interpretation of Imaging (X-ray, MRI)
Astrid van Tubergen Epidemiology of Axial SpA
Fred Houssiau Updates in the Management of Renal Disease in SLE
Speaker TBC Cardiovascular Risk Management in SLE
Speaker TBC Family Planning in SLE
Thomas Dörner Treatment Goals and Disease Activity Assessment in SLE
Georg Schett Osteoimmunology
Rik LoriesPiet Geusens
Bone Biology and Novel Osteoporosis Agents
Stephen HallNicolò Pipitone
Managing Vasculitis
Dominique Baeten Updates in Basic Immunology
Athol Wells Interstitial Lung Disease
Mini-Symposium
THE FOURTH INTERNATIONAL IMMUNOLOGY SUMMITClinical Implications of Scientific Breakthroughs in Immune-Mediated Diseases
21st to 23rd February 2013, Prague, Czech RepublicChaired by Peter Nash
CME accreditation applied for
On behalf of myself and our faculty of distinguished specialists I am delighted to invite you to join us at the Fourth International Immunology Summit.
Within the fi eld of immunology, analogous to the challenge of climbing a mountain, we have faced a steep climb in the treatment of our patients. Our initial goals of symptom control and disease modifi cation have been surpassed in many cases, and we continue to advance up the treatment pyramid as our focus increasingly shifts to remission and drug-free remission. This meeting will consider the scientifi c data and clinical guidance that can help us to continue this advance, and will close with discussions of our hopes for the future, of reaching the peak of management through the cure, and ultimately prevention of immunological conditions.
This meeting will review the latest scientifi c developments across immune-mediated diseases and consider how these novel updates can be implemented in the clinic to improve the care of our patients. The programme will cover a wide range of relevant topics including:• New pathways and targets in immunology• Managing comorbidities in rheumatologic diseases• Scientifi c approaches to early aggressive treatment in RA and translation of clinical
trial data into daily practice• Pathogenesis of axial SpA and PsA and novel management approaches• Future developments in rheumatic disease imaging • Novel pathways and therapies in SLE • Novel pathways and therapies in osteoporosis
The Summit will provide the opportunity for discussion, interaction, networking and debate with many leading experts in their respective fi elds.
The meeting will start at 11am on the morning of Thursday 21st February and fi nish at lunchtime on Saturday 23rd February. In addition to the main plenary sessions you will have the opportunity to attend up to four highly interactive ‘mini-symposia’ sessions, providing the opportunity to consider the most novel developments across a wide range of topics most relevant to the management of our patients.
I very much look forward to welcoming you to what promises to be a highly exciting, interactive and enjoyable meeting.
Kind regards
Peter Nash MBBS (hons) FRACP (Course Director)Associate Professor, Department of Medicine, University of QueenslandDirector of the Rheumatology Research Unit, Sunshine Coast, Australia
Thursday 21st February 2013
1000 – 1100 Arrivals and Coffee
1100 – 1110 Welcome and Introduction from the Course Director Peter Nash (Australia)
Updates in Immunology
1110 – 1140 New Pathways and Targets in Immunology Dominique Baeten (NL)
1140 – 1210 Introduction of Novel Agents – Implications for Clinical Practice
Peter Taylor
1210 – 1220 Questions and Answer Session
1220 – 1330 Lunch
Management of Rheumatological Diseases
1330 – 1400 Managing Comorbidities in Rheumatologic Diseases Len Calabrese (US)
1400 – 1430 Family Planning and Pregnancy in Immunological Disease
Speaker to be confi rmed
1430 – 1500 Advances in Interstitial Lung Disease – Classifi cation, Investigation & Management
Athol Wells (UK)
1500 – 1515 Questions and Answer Session
1515 – 1545 Coffee
Rheumatoid Arthritis
1545 – 1615 Biologic Agents – An Update of Safety Data Xavier Mariette (France)
1615 – 1645 Early and Aggressive Management of RA Speaker to be confi rmed
1645 – 1715 Translating Trial Data into Clinical Practice Josef Smolen (Austria)
1715 – 1730 Questions and Answer Session
1730 – 1900 Mini-Symposium Session 1
2000 Buffet Dinner
Friday 22nd February 2013
axSpA and PsA
0830 – 0900 Pathogenesis and Novel Targets in PsA Chris Ritchlin (US)
0900 – 0930 Update on Trials and Novel Therapies in PsA Doug Veale (Ireland)
0930 – 0940 Questions and Answer Session
ProgrammeDear Colleagues and Friends,
0940 – 1010 Coffee
1010 – 1040 Axial SpA – Pathogenesis and Burden of Disease Désirée van der Heijde (NL)
1040 – 1110 Update on Trials and Novel Therapies in SpA Filip van den Bosch (Belgium)
1110 – 1120 Questions and Answer Session
1120 – 1250 Mini-Symposium Session 2
1250 – 1420 Lunch
1420 – 1500 Future Developments in Rheumatic Disease Imaging Robert Landewé (NL)
SLE
1500 – 1530 Basic Science – Pathogenesis of SLE Thomas Dörner (Germany)
1530 – 1600 Novel Therapies in SLE Joan Merrill (USA)
1600 – 1615 Questions and Answer Session
1615 – 1645 Coffee
1645 – 1815 Mini-Symposium Session 3
2000 Summit Dinner
Saturday 23rd February 2013
0830 – 1000 Mini-Symposium Session 4
1000 – 1030 Coffee
Bone Biology
1030 – 1100 Updates in Osteoporosis Eugene McCloskey (UK)
1100 – 1130 Novel Pathways in Osteoporosis Christian Roux (France)
1130 – 1140 Questions and Answer Session
1140 – 1210 Reaching the Summit – The Future of Immunological Disease Management
Speaker to be confi rmed
1210 – 1230 Meeting Summary and Close
1230 – 1330 Lunch
Programme may be subject to minor changes
top related